Heparin is well-known as an anti-coagulant, antithrombotic drug. Chemically, it is a linear polysaccharide that is derived from animal tissues. For some time it has been known that heparin is not a homogeneous substance; rather, it is a heterogeneous mixture of molecules ranging in molar mass from less than 5,000 to more than 30,000 Daltons. Heparin can be chemically or enzymatically depolymerized to obtain low molecular weight (LMW) heparin products, which exhibit an improved pharmacological profile.
Heparin is well-known as an anti-coagulant, antithrombotic drug. Chemically, it is a linear polysaccharide that is derived from animal tissues. For some time it has been known that heparin is not a homogeneous substance; rather, it is a heterogeneous mixture of molecules ranging in molar mass from less than 5,000 to more than 30,000 Daltons. Heparin can be chemically or enzymatically depolymerized to obtain low molecular weight (LMW) heparin products, which exhibit an improved pharmacological profile.
The U.S. Food and Drug Administration (FDA) has scrutinized LMW-heparin products closely due to their inherent variability and polydispersity. Previously, these materials had to be characterized by relative techniques involving viscometry or standard elution-based chromatographic methods. Fortunately, the advent of multi-angle laser light scattering combined with SEC means that authentic calibration standards derived from heparin are no longer necessary. LMW-heparins may now be characterized absolutely–without regard for the molecules' elution time or conformation in solution.
Figure 1
For this application note, Scientific Protein Laboratories (Waunakee, WI), a subsidiary of American Home Products Corporation, analyzed three commercial LMW heparin products. They employed a Waters 510 pump and 401 refractometer, a Shodex OHpak SB-803HQ analytical column (8.0 × 300 mm) with an SB-G guard column, and a miniDAWN, triple angle light scattering instrument. The mobile phase was 0.1 M ammonium acetate, and the specific refractive index increment, dn/dc was measured off-line in an Optilab operating at the same wavelength as the miniDAWN. Details of this study were published in Analytical Biochemistry 245, 231–241 (1997).
The results show unequivocally the power of the miniDAWN to resolve the three LMW-heparin products, each of which was manufactured by a different depolymerization process. Wyatt Technology's ASTRA software indicates that clear differences exits in these products' differential molar mass distributions (Figure 2).
Figure 2
We sincerely thank James Knobloch and Dr. Patrick Shaklee, Scientific Protein Labs, for sharing these data with us and permitting us to publish their results.
DAWN®, miniDAWN®, ASTRA®, Optilab®, and the Wyatt Technology logo are registered trademarks of Wyatt Technology Corporation.
Wyatt Technology Corporation
6300 Hollister Avenue, Santa Barbara, CA 93117
tel.(805)681-9009, fax (805)681-0123
Website: www.wyatt.com
Direct Analysis of Class 2 Residual Solvents Using Molecular Rotational Resonance Spectroscopy
February 19th 2025Molecular rotational resonance (MRR) spectroscopy operates in the microwave region, detecting transitions between pure rotational energy levels. Combined with adiabatic cooling, MRR produces highly selective spectra unique to each molecule’s atomic structure. Even slight changes in atomic position or mass result in distinct spectral differences, allowing MRR to directly analyze complex mixtures, including isomers, without chromatographic separation. This article presents a continuous headspace-MRR method for analyzing Class 2 residual solvents, including low-volatility solvents from Class 2 Mixture C. By evaluating solvents with diverse boiling points, the study demonstrates that MRR meets ICH and USP standards for most Class 2 and Class 3 solvents and half of Class 1 solvents.
Revolutionizing LC-MS with Next-Gen Separation for Cyclic Peptide Analysis
February 17th 2025Cyclic peptides, known for their stability and high specificity, are promising therapeutic agents in the fight against cancer, infections, and autoimmune diseases. However, developing effective cyclic peptides presents numerous challenges, including poor pharmacokinetics, efficacy, and toxicity. Traditional methods like liquid chromatography tandem-mass spectrometry (LC-MS/MS) often struggle with resolving isomeric linear peptide metabolites, posing significant risks in safety, efficacy, and regulatory approval. In this paper, Komal Kedia, PhD, will share how she leveraged MOBIE’s high-resolution ion mobility-mass spectrometry (IM-MS) system to achieve a 72% reduction in run times, 200% greater resolving power, and enhanced accuracy in identifying “soft spots” prone to enzymatic degradation.